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Introduction
Foralongtime,theanti-metabolite5-fluorouracil(5-FU)has beenthesoletreatmentforpatientswithmetastaticcolorectal cancer (mCRC). Further attempts to enhance its efficacy centered on its co-administration with leucovorin (LV) [1] . Additionally, improved survival has been achieved over the last decade with the introduction of newer cytotoxic drugs, such as irinotecan and oxaliplatin [2, 3] . Two large randomized clinical trials have shown that irinotecan combined with 5-FU/LV (FOLFIRI or bolus IFL) significantly improvedresponserates(RRs),timetoprogression(TTP),and overall survival (OS) [3, 4] . Based on data from these and other trials [3] [4] [5] [6] [7] , the combination regimens FOLFIRI and oxaliplatin/5-FU/LV (FOLFOX) became the new standard treatments of mCRC. In addition, improvements in efficacy were achieved when therapeutic antibodies were combined withchemotherapy [8, 9] . AsmCRCisthesecondmostcommoncauseofdeathfrom cancerinWesterncountries [10] ,theseadvancesintreatment capabilitiesareofhighrelevance.However,themedianageof patients participating in clinical trials is typically 10 years below the median age at first diagnosis in the wider patient population(e.g.,71yearsintheUSA).Infact,CRCwasreportedtobethemostcommoncancerintheUSAinpatients whowere≥75yearsold [11] .Asaconsequenceofthelower representationofelderlypatientsinclinicaltrials,theknowledgeofefficacyandtoxicitiesoftherapeuticregimensinthis age group is often considerably limited. Co-morbidity, age limits in inclusion criteria, functional status, concerns with respect to toxicity, and logistical reasons relating to lack of social support for some elderly patients may all be common barrierstoinclusion [12] .Assumedlyforsimilarreasons,this lower use of chemotherapy for elderly patients extends to thosetreatedoutsideclinicaltrialsincommunitysettings [13, 14] .Furthermore,asmanyofsuchsmall,non-academiccommunity-basedoutpatientclinicsmightbeslowerinadaptingto new combination protocols, data from such institutions may bequitedifferenttothoseusuallypresentedfromlargetrials.
Eventhoughthecombinationofirinotecanwith5-FU/LV hasbeendemonstratedtoimproveRRsandprogression-free survival(PFS)in4randomizedstudies,andhasshownasignificantOSbenefitin2suchstudies,theadvantageinefficacy wasassociatedwithincreasedtoxicity [3] [4] [5] .Inconsideration ofthisfact,specificdataregardingtheefficacyandtoxicityof irinotecan-basedcombinationsinelderlypatientstreatedoutsideclinicaltrialsarestillrare,butofgreatimportance.This prospective observational study was undertaken to extend earlierobservationsandtoanalyzetherelativeperformance oftheweeklyschemecomparedwiththebiweeklyschemeof irinotecan-based chemotherapy in both elderly (≥ 70 years) and younger (< 70 years) patients, with high emphasis on a typicalcommunity-basedoutpatientpopulation.
Methods
Patients with advanced CRC or mCRC who received first-, second-, or third-linechemotherapywereeligibleforentryinthistrial.Histological confirmation of adenocarcinoma of the colon or rectum and at least 1metastaticlesionoradvanceddiseasewasrequired.AdditionalrecruitmentcriteriawereaKarnofskyindex>60%,atleast1measurablelesion, normalmajororganfunction,andageabove18years.Allpatientsgave writteninformedconsenttotreatment.
Thiswasaprospective,observational,open-label,multi-centric,German-widephaseIVstudy.Datafrom601patientswhoreceivedirinote-can-basedchemotherapyfromSeptember2003toFebruary2006in108 different German institutions, mostly office-based oncologists and community-based outpatient clinics, were analyzed. Patients were consecutivelyrecruited,accordingtowhethertheyhadreceivedaweeklyregimen ) on day 1, followed by a 46-h continuousinfusionof5-FU(2400mg/m 2 )).Furthermore,subjectswere dividedinto2agegroups:elderly(≥70years)andyounger(<70years) patients.Additionally,theywereplacedinto4groupsaccordingtotheir prior treatment: first-line therapy (only surgery), first-line therapy (surgery + adjuvant therapy), second-line therapy (palliative therapy with FOLFOX regimen), or third-line therapy (2 palliative therapies: first 5-FU, then FOLFOX regimen). Treatment continued until first documented tumor progression under therapy or severe therapy-associated toxicities.EndpointswereTTP,OS,response,andsafety.
Tumorresponseclassificationwasbasedonthedefinitionssetoutin the response evaluation criteria in solid tumors (RECIST) [15] . Radiologicalassessmentswereconductedatthediscretionofthetreatingphysician.Thefollowingparameterswerecalculated:RR,TTP,andOS.The tumor growth control rate (TCR) was defined as: complete response (CR)+partialresponse(PR)+stabledisease(SD).Toxicitywasdefined asthefrequencyofhematologicalandnon-hematologicalchemotherapyassociatedadverseeventsandlaboratorychangesafter3monthsoftreat-ment. Toxicity was evaluated at all visits and graded 1-4 using the National Cancer Institute Common Toxicity Criteria (NCI-CTC) version 2.0. For each toxic event, the documented maximum NCI-CTC grading wastakenintoaccount.Particularemphasiswasplacedonthemanagementoflate-onsetdiarrhea.
The statistical analysis was performed using the full analysis set (intent-to-treat).Statisticalanalysisincludingsurvivalanalysisaccordingto Kaplan-Meier was performed with the SAS software package. Survival wasmeasuredfromthetimeoffirstdiagnosisofmetastaticdiseasetothe dateofdeathorlastfollow-up.TTPwascalculatedfromthefirstdayof treatment until progression. Differences in OS, TTP, and RR between studygroupswereanalyzedbyχ 2 test.Valuesofsignificancewerecalculatedvia Fisher'stest,andp <0.05wasconsideredsignificant.
Results
Atotalof601patientswereenrolledandincludedinthein-tent-to-treat analysis of this prospective trial, 181 of whom were70yearsorolder.Themedianageofthesepatientswas 65 years, ranging from 28 to 87 years. 405 patients were treatedweeklywhile68receivedabiweeklyschedule.Allpatientshadundergonesurgerypriortochemotherapy,31had only undergone surgery. 186 patients had received 2 earlier adjuvanttherapies.For235subjects,thiswassecond-line,and
Moehler/Ababneh/Verpoort/Schmidt/ Musch/Soeling/Maintz/Siebler/Schimanski/ Galle/Fahlke tientsdidnotexperienceagreaterlevelofgrade3/4toxicities than non-elderly patients, except for late-onset diarrhea, which was more frequent in this group (16% at ≥70 years; 7.1% at < 70 years). Within the treatment arms, grade 3/4 toxicitieswereobservedlessofteninthebiweeklythaninthe weeklyarm,inwhich10.9%ofgrade3/4late-onsetdiarrhea was reported compared to 1.5% for the patients treated biweekly. Other toxicity rates did not deviate significantly withinbothgroups.Grade3/4thromboemboliccomplications wereencounteredin2subjects.
Comparisonsforresponseweremadebetweenelderlyand youngerpatients,betweenthetreatmentarms,andwithinthe groups divided according to prior treatment (tables 4-6). Whencomparingagegroups(table4),theTCRwasmarginfor 32 patients, this was third-line palliative chemotherapy. The patient demographics and baseline characteristics are summarizedintable1.Ingeneral,parameterswerebalanced between the investigated groups. 66% of the individuals enrolledinthisstudyweremale.Themedianobservationperiod was5.8months(0-38months).
The frequencies of hematological and non-hematological toxicitiesarelistedbyagegroupintable2andbytreatment groupintable3.Toxicitiesweremildtomoderateinthemajorityofpatients.Late-onsetdiarrheawas,withanincidence of9.8%,themostfrequentlyreportedgrade3/4toxicity,followedbypain(4.7%),nausea(4.3%),alopecia(4.3%),earlyonset diarrhea (3.7%), and neutropenia (2.8%) as the most frequenthematologicaladverseevent.Ingeneral,elderlypa- 
Discussion
To our knowledge, this is the largest published German observational study analyzing the relative performance of the weekly scheme compared with the biweekly scheme of irinotecan-basedchemotherapyinbothelderly(≥70years)and younger(<70years)patients,withhighemphasisplacedon typicalcommunity-basedoutpatientclinicsnotalwaysparticipating in other clinical mCRC trials. The patients included wererecruitedbymanyoutpatientclinicsthatarelessexperiencedwithclinicalstudies.Thus,weproposethattheseclinics are clearly different from the high-recruiting centers usually participating in large registration trials, but represent the drug-prescribingcentersbroadlyseeninmCRCpatientcare formanyEuropeanandnon-Europeancountries.Thisisalso likelytobethereasonwhysomeisolateddatawerenotdocumentedforafewpatients. Today, the combination of irinotecan with FU/FA is acceptedasoneofthestandardfirst-linetherapiesformCRC. ProspectiverandomizedstudiesdemonstratedthatthiscombinationimprovedOSorPFScomparedtoprotocolswithout irinotecan [3] [4] [5] .ForGermany,in2007,37%ofregimesused infirst-linechemotherapyforpatientswithmCRCwereirinotecanbased,ofwhich32%wereschedulesincorporatingiri-notecan + 5-FU/FA (Moehler, personal communication). However,elderlypatientshaveoftenbeenexcludedorunderrepresented in these studies considering the increased levels oftoxicityassociatedwithcombinationtherapy,althoughthey wasnotablethatthehigherincidenceofgrade3/4late-onset diarrheawasinthe≥70-year-oldgroup(16%vs.7.1%).Lateonsetdiarrheawasthegreatestclinicaltoxicityforallpatients (9.8%).However,thegrade3/4diarrhea(latediarrhea16%; earlydiarrhea4.4%)inpatientsof≥70yearswasequivalent incomparisontootherprotocolsincludingelderlyindividuals [21, 22] .Inaddition,theseratesareinlinewiththosereported earlierinsimilarstudiesnotrestrictedtoelderlyparticipants [3, 5] .
Inatrialof30patientsaged70-84years,withpreviously untreated mCRC, receiving 5-FU/LV + irinotecan, toxicities were generally manageable, even though there was 1 death relatedtoneutropenicsepsis.Grade3/4neutropeniaanddiar-rheawerereportedin20%and17%ofsubjects,respectively [22] .Furthermore,thesafetyprofileoftherecentmeta-analysisincorporating599patientsaged≥70years [17] wasfavorably comparable with our study. Toxicity patterns were not significantlydifferentbetweentheolderandyoungergroups, except for increased hepatic toxicity among the elderly patients. Additionally, it seems worthy to mention that, in our study,grade3/4toxicitieswereobservedlessofteninthebi-weeklythanintheweeklyschedule,inwhich10.9%ofgrade 3/4 late-onset diarrhea was reported compared to 1.5% for the biweekly patients. Moreover, we found higher grade 3/4 gastrointestinaltoxicityratesamongthegrouptreatedweekly (11.9%vs.1.5%; p=0.0093).However,severegastrointestinaltoxicityorthromboembolicevents(0.33%forallpatients) wereneverfatal.Toxicdeathwasrecordedin1case.
Consideringtheoutcomebasedonlyonchronologicalage, it may not always be representative of the real 'biological' age,whichmayalsobeaselectionbiasinthisstudyasphysicians intend to treat only fit elderly patients. Since geriatric assessment and the recording of co-morbidities and concurrentmedicationshavenotbeenincludedinthistrial,theconclusions of the study may not be fully generalized for the wholepopulationoftheelderlypatients.
Conclusions
Insummary,particularlythebiweeklyirinotecan-basedregimenwaswelltoleratedandusefulforefficienttumorcontrol inoutpatientsettingsofnon-university-basedoutpatientclinics. The results also prove the feasibility of irinotecan-based polychemotherapy in fit elderly advanced-CRC patients. Findingsintermsofefficacyandtoleranceareinkeepingwith those previously published. Data of our study demonstrate thatelderlypatientsingoodgeneralconditionshouldnotbe excluded from combination chemotherapy with irinotecan just because of advanced age. We conclude that the entire clinical condition of the patient, and not simply their age, shouldbeincorporatedintheassortmentofsuitabletherapy andtherapeutictrialdesigns.
represent the majority of patients for this pathology. Therefore, we conducted this prospective, observational study incorporating a relatively high proportion of individuals of ≥70years(30.1%)usingirinotecan-basedchemotherapiesin the setting of small, non-university, community-based outpatient clinics. Although this proportion is relatively high in comparison to other studies, it is still lower than the proportion of elderly patients in the general CRC population. Thisshowsonceagainthatelderlypatientsmaystillbeundertreated, which may also be explained by the greater risk for co-morbidities, impaired functional or mental status, or logistical reasons, clearly indicating that further studies are especiallyimportantinfrailpatients.
Safety and RRs were remarkably positive for both elderly and younger patients. Consistent with other large trials [3, 4] ,weobtainedRRsof37.5%(<70years)and31.5% (≥70years).TTPandOSweresimilartopreviouslyreported results [3, 4] . Again, our efficacy results compare favorably with those obtained with standard FOLFIRI or FOLFOX regimens [2, 3] . In 683 patients, Saltz et al. [4] showed a significant improvement in median PFS and OS (14.8 vs. 12.6months)andtheRRswerealmostdoubled(39%5-FU/ LV + irinotecan vs. 21% 5-FU/LV, respectively). Furthermore,ourresultsareinaccordancewithaphaseIIstudyusing FOLFIRI for patients aged at least 70 years conducted by François et al. [16] . An RR of 40%, a median TTP of 8.0monthsandamedianOSof17.2monthswereobserved. TheRRinadditiontotheTCRnotedinouranalysis(78%at <70yearsand73%inpatients≥70years)comparewellwith thatstudy(85%),althoughthiswassecond-lineorthird-line treatmentformorethanhalfofthepatientsinourtrial.Even forthird-linetherapy,medianTTPstandsat6.4monthsinour patients.
In one of the largest evaluations to date of age-related treatmenteffectsinaCRCpopulation,arecentmeta-analysis [17] compared data from 4 randomized trials of irinotecan + 5-FU/FA versus 5-FU/FA alone. Elderly (≥ 70 years; n =599)andyounger(<70years;n =2092)patientshadsimilarresponse,TTPandOSrates.Thedataobtainedforelderly patients are comparable to our study (RR 50.5% vs. 31.5%; TTP9.2vs.7.9months;OS17.6vs.19.4months,respectively). Here, the difference in RR could also be explained by the highproportionofpatientsbeingtreatedinsecondandthird lineinouranalysis.
InagreementwiththefindingsofphaseIIItrials [18, 19] , thepackageinsertforirinotecanrecommendsalowerdosein elderly patients if this agent is used as monotherapy. However,theseresultsarenotsupportedbyamorerecentsecondlineirinotecantreatmentinpatientswhofailedfluoropyrimidine-based therapy, revealing that the toxicity of irinotecan monotherapy was not significantly worse in 72 elderly comparedwith267youngerpatients [20] .Thesafetyprofilewas good in our study. The incidence of grade 3/4 toxicities was similar in both age groups. Regarding toxicity differences, it
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